Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights
This article was originally published in The Tan Sheet
Executive Summary
Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds